Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective

References

• IDF.org [Internet]. Diabetes facts & figures. Brussels: International Diabetes Federation; 2021 Dec 9 [cited 2022 Feb 11]. Available from: https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
   Google Scholar
• Insulin — the new battleground for drug pricing [Editorial]. Nat Biotechnol. 2022;40(1):1.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Bose S, Gowda S, et al. Biosimilar insulins – what a clinician needs to know? Indian J Endocrinol Metab. 2019;23(4):400–406.
   PubMedGoogle Scholar
• Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. Diabet Med. 2017;34(10):1340–1353.
   PubMed Web of Science ®Google Scholar
• FDA.gov [Internet]. Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: guidance for industry. Silver Spring (MD): U.S; 2019 May [cited 2022 Mar 3]. Available from: https://www.fda.gov/media/124907/download.
   Google Scholar
• Diabetes.org.uk [Internet]. Biosimilar insulins: position statement. London: Diabetes UK; 2019 Aug. [cited 2021 Oct 2]. Available from: https://www.diabetes.org.uk/resources-s3/2019-09/Biosimilars%20PS%20Final.pdf
   Google Scholar
• FDA.gov [Internet]. Food and Drug Administration. Biosimilars and interchangeable biosimilars: licensure for fewer than all conditions of use for which the reference product has been licensed. Guidance for industry. DRAFT GUIDANCE;. Silver Spring (MD): U.S; 2020 Feb. [cited 2022 Mar 3]. Available from: https://www.fda.gov/media/134932/download
   Google Scholar
• FDA.gov (Internet). Silver Spring (MD): U.S. Food & Drug administration scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry; 2015 Apr. [cited 2021 Oct 2]. Available from: https://www.fda.gov/media/82647/download.
   Google Scholar
• FDA.gov [Internet]. Biosimilar guidances. Silver Spring (MD): U.S. Food & Drug Administration; 2021 Oct 5. [cited 2022 Mar 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/general-biologics-guidances/biosimilars-guidances.
   Google Scholar
• EMA.Europa.org [Internet]. Biosimilars in the EU: information guide for healthcare professionals. Amsterdam: European Medicines Agency; [cited 2022 Mar 7]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
   Google Scholar
• EMA.Europa.org [Internet]. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. London: European Medicines Agency; 2015 Feb 26. [cited 2022 Mar 7]. Available from 2022 Mar 7: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-clinical-development-similar-biological-medicinal-products-containing_en-0.pdf.
   Google Scholar
• EMA.Europa.Eu [Internet]. London: European medicines agency. Guideline on similar biological medicinal products; 2014 Oct 23. [cited 2021 Oct 2]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf
   Google Scholar
• Kirchhoff CF, Wang XM, Conlon HD, et al. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114:2696–2705.
   PubMed Web of Science ®Google Scholar
• Heinemann L, Khatami H, McKinnon R, et al. An overview of current regulatory requirements for approval of biosimilar insulins. Diabet Technol Ther. 2015;17(7):510–526.
   PubMed Web of Science ®Google Scholar
• Cohen HP, Lamanna WC, Schiestl M. Totality of evidence and the role of clinical studies in establishing biosimilarity. In: Gutka H, Yang H, Kakar S, editors. Biosimilars. AAPS advances in the pharmaceutical sciences series. Vol. 34. Cham: Springer; 2018. pp. 601–628. DOI: 10.1007/978-3-319-99680-6_22.
   Google Scholar
• Markus R, Liu J, Ramchandani M, et al. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. Biodrugs. 2017;31(3):175.
   PubMed Web of Science ®Google Scholar
• Kim AP, Bindler RJ. The future of biosimilar insulins. Diabet Spectr. 2016;29(3):161–166.
   PubMedGoogle Scholar
• Avila AM, Bebenek I, Bonzo JA, et al. An FDA/CDER perspective on nonclinical testing strategies: classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol. 2020;114(2020):104662.
   PubMedGoogle Scholar
• Ben Ray Luján U.S. Senator for New Mexico [Internet]. Luján introduces legislation to reduce animal testing. Washington (DC): Senator Ben Ray Luján; 2022 May 20. [cited 2022 Jul 25]. Available from: https://www.lujan.senate.gov/newsroom/press-releases/lujan-introduces-legislation-to-reduce-animal-testing/
   Google Scholar
• FDA.gov [Internet]. Food & Drug Administration. Biosimilar development process. Silver Spring (MD): U.S; [cited 2022 Mar 7]. Available from: https://www.fda.gov/media/113355/download
   Google Scholar
• FDA.gov [Internet]. Food and Drug Administration. Clinical immunogenicity considerations for biosimilar and interchangeable insulin products: guidance for industry. DRAFT GUIDANCE. Silver Spring (MD): U.S; 2019 Nov. [cited 2022 Mar 4]. Available from: https://www.fda.gov/media/133014/download.
   Google Scholar
• Blauvelt A, Cohen AD, Puig L, et al. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. Br J Dermatol. 2016;174(2):282–286.
   PubMed Web of Science ®Google Scholar
• FDA.gov [Internet]. Food & Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. Guidance for industry. DRAFT GUIDANCE. Silver Spring (MD): U.S; 2019 May. [cited 2021 Oct 2]. Available from: https://www.fda.gov/media/125484/download
   Google Scholar
• World Health Organization (WHO). Annex 2: guidelines on evaluation of similar biotherapeutic products (SBPs) - sixtieth report. WHO Expert Committee on Biological Standardization; 2013. (WHO Technical Reports series; no. 977).
   Google Scholar
• Niazi SK, [Internet]. The center for biosimilars. No animal testing of biosimilars—US congress begins amendment to BPCIA. Chicago (IL): AJMC; 2022 Jun 27. [cited 2022 Jul 25]. Available from: https://www.centerforbiosimilars.com/view/contributor-no-animal-testing-of-biosimilars-us-congress-begins-amendment-to-bpcia
   Google Scholar
• Blevins TC, Barve A, Raiter Y, et al. Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: results of the INSTRIDE-3 phase 3 switch study. Diabet Obes Metab. 2020;22:365–372
   PubMed Web of Science ®Google Scholar
• Kurki P, Barry S, Bourges I, et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81:1881–1896.
   PubMed Web of Science ®Google Scholar
• Barbier L, Ebbers H, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734–755.
   PubMed Web of Science ®Google Scholar
• Health.gov.au [Internet]. Who chooses whether the biosimilar medicine or the reference biological medicine is used? Canberra: Australian Government Department of Health; 2019 Feb 22. [cited 2022 Mar 3]. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/biosimilar-hp-who-chooses-whether-biosimilar-medicine-or-reference-biological-medicine-is-used
   Google Scholar
• Canada.ca [Internet]. Biosimilar biologic drugs in Canada: fact sheet. Ottawa (ON): Office of Policy and International Collaboration; 2018 Aug 23. [cited 2022 Mar 3]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/Fact-Sheet-EN-2019-08-23.pdf
   Google Scholar
• Ascef BO, da Silva RG, HA O Jr, et al. Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making? Cad Saúde Pública. 2019;35(9):e00087219.
   PubMed Web of Science ®Google Scholar
• Gabionline.net [Internet]. Generics and Biosimilar Initiative. Naming and interchangeability for biosimilars in Japan; 2016 Oct 7. [cited 2022 Mar 3]. Available from: https://www.gabionline.net/reports/Naming-and-interchangeability-for-biosimilars-in-Japan
   Google Scholar
• Centerforbiosimilars.com [Internet]. AJMC - the center for biosimilars. Indian biosimilar standards: a work in progress; 2021 Apr 5. [cited 2022 Mar 3]. Available from: https://www.centerforbiosimilars.com/view/indian-biosimilar-standards-a-work-in-progress
   Google Scholar
• Kurki P. No need for systematic switch studies to demonstrate interchangeability of biosimilars. GaBI J. 2022;11(1):5–6.
   Google Scholar
• Wolff‑Holz E, Tiitso K, Vleminckx C, et al. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33:621–634.
   PubMed Web of Science ®Google Scholar
• FDA.gov [Internet]. Food & Drug Administration. FDA approves first interchangeable biosimilar insulin product for treatment of diabetes. Silver Springs (MD): U.S; 2021 Jul 28. [cited 2021 Oct 4]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-interchangeable-biosimilar-insulin-product-treatment-diabetes.
   Google Scholar
• Garg SK, Rewers AH, Akturk HK. Ever-increasing insulin-requiring patients globally. Diabetes Technol Ther. 2018;20(2):S2-1-S2–4.
   Google Scholar
• Diabetesatlas.org [Internet]. IDF Diabetes Atlas, 10th edn. Brussels: International Diabetes Federation; 2021 [cited 2022 Feb 22]. Available from: https://www.diabetesatlas.org
   Google Scholar
• Cefalu W, Dawes D, Gavlak G, et al. Insulin access and affordability working group: conclusions and recommendations. Diabet Care. 2018;41:1299–1311.
   PubMed Web of Science ®Google Scholar
• Haiweb.org [Internet]. Inequities and inefficiencies in the global insulin market: fact sheet 1; 2015 Nov. [cited 2021 Oct 2]. Available from: https://haiweb.org/wp-content/uploads/2015/11/ACCISS-Fact-Sheet-1-Inequalities-in-Insulin-Market.pdf
   Google Scholar
• Sriram S, Khan MM. Effect of health insurance program for the poor on out-of-pocket inpatient care cost in India: evidence from a nationally representative cross-sectional survey. BMC Health Serv Res. 2020;20(1):839.
   PubMed Web of Science ®Google Scholar
• Wirtz V, Hogerzeil H, Gray A, et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403–476.
   PubMedGoogle Scholar
• Downtoearth.org.in [Internet]. Millions of diabetes patients may not have access to insulin by 2030. New Delhi: DownToEarth; 2018 Nov 23. [cited 2021 Oct 4]. Available from: https://www.downtoearth.org.in/news/health/-millions-of-diabetes-patients-may-not-have-access-to-insulin-by-2030–62241
   Google Scholar
• Heinemann L. Biosimilar insulins and costs: what can we expect? J Diabetes Sci Technol. 2016;10(2):457–462.
   Google Scholar
• Gotham D, Barber MJ, Hill A. Production costs and potential prices for biosimilars of human insulin and insulin analogues. BMJ Glob Health. 2018;3:e000850.
   PubMed Web of Science ®Google Scholar
• Satheesh G, Unnikrishnan MK, Sharma A. Challenges constraining availability and affordability of insulin in Bengaluru region (Karnataka, India): evidence from a mixed-methods study. J Pharm Policy Pract. 2019;12(1):1–11.
   PubMedGoogle Scholar
• Barbier L, Simoens S, Vulto AG, et al. European stakeholder learnings regarding biosimilars: part I-improving biosimilar understanding and adoption. Biodrugs. 2020;34(6):783–796.
   PubMed Web of Science ®Google Scholar
• Gabionline.net [Internet]. Generics and Biosimilar Initiative. Domestic biologicals cost less in India. 2016 Jan 22. [cited 2021 Oct 4]. Available from: https://www.gabionline.net/biosimilars/research/Domestic-biologicals-cost-less-in-India
   Google Scholar
• Barbier L, Simoens S, Vulto AG, et al. European stakeholder learnings regarding biosimilars: part II—improving biosimilar understanding and adoption. Biodrugs. 2020;34(6):797–808.
   PubMed Web of Science ®Google Scholar
• IDF.org [Internet]. IDF Europe position paper on biosimilars in treatment of people with diabetes. Brussels: International Diabetes Federation; 2017 Nov. [cited 2021 Oct 4]. Available from: https://www.idf.org/images/IDF_Europe_Position_on_Biosimilars.pdf
   Google Scholar
• Biosimilardevelopmet.com [Internet]. Pennsylvania: Biosimilar Development. Global biosimilar insulin market opportunity and clinical insight outlook 2022; 2017 Jun 28. [cited 2021 Oct 4]. Available from: https://www.biosimilardevelopment.com/doc/global-biosimilar-insulin-market-opportunity-and-clinical-insight-outlook-0001
   Google Scholar
• Biosimilarscouncil.org [Internet]. Insulin biosimilars white paper. Washington (DC): Biosimilars Council; 2019 May 16. [cited 2021 Oct 4. Available from: https://biosimilarscouncil.org/resource/insulin-biosimilars-white-paper/
   Google Scholar
• Griffith N, Mcbride A, Stevenson J, et al. Formulary selection criteria for biosimilars: considerations for US health-system pharmacists. Hosp Pharm. 2014;49(9):813–825.
   PubMedGoogle Scholar
• Prnewswire.com [Internet]. Mylan and Biocon announce U.S. FDA approval of Semglee™ (insulin glargine injection). Cleveland (OH): Cision Distribution; 2020 Jun 11. [cited 2022 Mar 3]. Available from: https://www.prnewswire.com/news-releases/mylan-and-biocon-announce-us-fda-approval-of-semglee-insulin-glargine-injection-301074847.html
   Google Scholar
• Danne T, Heinemann L, Bolinder J. New insulins, biosimilars, and insulin therapy. Diabetes Technol Ther. 2021;23(S2):S46–S68.
   PubMedGoogle Scholar
• Biocon.com [Internet]. Bangalore: Biocon. Biocon Biologics and Viatris Inc. receive historic approval for first interchangeable biosimilar Semglee® (insulin glargine-yfgn injection) for the treatment of diabetes; 2021 Jul 29. [cited 2021 Oct 4]. Available from: https://www.biocon.com/biocon-biologics-and-viatris-inc-receive-historic-approval-for-first-interchangeable-biosimilar-semglee-insulin-glargine-yfgn-injection-for-the-treatment-of-diabetes/
   Google Scholar
• Blevins T, Barve A, Sun B, et al. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: results of the INSTRIDE 1 phase III study. Diabet Obes Metab. 2018;20(8):1944–1950.
   PubMed Web of Science ®Google Scholar
• Blevins T, Barve A, Sun B, et al. Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: results of the phase III INSTRIDE 2 study. Diabet Obes Metab. 2019;21:129–135.
   PubMedGoogle Scholar
• Edwards CJ, Hercogová J, Albrand H, et al. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther. 2019;19(10):1001–1014.
   PubMed Web of Science ®Google Scholar